SmithRx IPO

www.smithrx.comHealthcare / Digital Health

With a focus on finding a better way to manage employee pharmacy benefits, SmithRx is a pharmacy benefit management (PBM) company that aims to use technology to connect employers and health plan members to specialized programs for pharmaceutical coverage. It provides a platform for small businesses so they can gain transparency and alternative methods to deliver pharmacy benefits. As a result, SmithRX strives to enable employees to access medications that are affordable and easy to acquire while also trying to reduce overhead costs for employers. SmithRx was was founded by Jake Frenz in 2016 and is headquartered in San Francisco, CA.

Buy or sell SmithRx stock Learn more about SmithRx stock

Learn more about SmithRx

Is SmithRx a publicly traded company?

SmithRx is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will SmithRx go IPO?

SmithRx has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is SmithRx's IPO price?

The IPO price for SmithRx will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in SmithRx pre-IPO?

SmithRx is privately held company and is not publicly traded, therefor investing in SmithRx pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my SmithRx shares?

To determine the value of your SmithRx shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your SmithRx shares. You can also learn more about how to sell your private shares before getting started.

Can you sell SmithRx before it goes public?

Yes, you can seek to sell shares in SmithRx while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

When was SmithRx founded?

SmithRx was founded in 2016.

Who are SmithRx's major investors?

Venrock

BoxGroup

Founders Fund

Great Oaks Venture Capital

Blumberg Capital

Catapult VC

FourCities Capital

NextGen Venture Partners

Metaplanet Holdings

SciFi VC

Precursor Ventures

Presight Capital

MCVC Partners

W Ventures

Highbury Group

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.